Yi Sheng Pharmaceutical: Ginseng Characteristics of proprietary Chinese medicine, product line Rich

Jilin ji ' an Yi Sheng Pharmaceutical Co., Ltd. the public issue of 27.6 million shares, after the issuance of the company's total share capital of not more than 110.32 million shares, the company's public distribution of public shares accounted for 25.09%. Benefit from industrial policy, the company shares the growth of the pharmaceutical industry in China, the pharmaceutical market has developed rapidly since the reform and opening up, the pharmaceutical industry's industrial output value from 2001 to 218.8 billion yuan to 2009 1.0382 trillion yuan, annual growth of 21%, 2010 is expected to exceed 1.2 trillion yuan.　　However, China's pharmaceutical market accounted for only 9% of the global market, far less than 19% of the population, with the increase in national income, health awareness and national industrial policy promotion, the future development of space is huge, the company is expected to grow rapidly with the industry. The company's competitive advantage lies in its characteristic products, research and marketing company product range, leading products are included in the National Health Insurance Directory, with 6 exclusive products, 4 national Traditional Chinese Medicine protection varieties and 2 national innovative new drugs, and relying on local raw material resources, quality controllable curative effect, the market response is good. At the same time, the company focused on research and development support, with a 62 people echelon complete research and development team, currently in the research of a number of new drugs and two development of existing products, with 3 invention patents and 3 patents in the patent, and participate in 6 Chinese Medicine National Quality standards, excellent research and development to provide a steady flow of power.　　Company management focus on marketing, over the years the company's professional quality, high loyalty of nearly thousands of people's marketing team continued to deep, woven marketing network covering all levels of the national market. Raise funds to expand production capacity, strengthen research and development capabilities the fund raised around the company's development strategy to enhance the company's leading product production capacity and research and development capabilities as the main goal. The funds are mainly used for the expansion of hard capsules and injection capacity and a provincial scientific research center. Expanding capacity will solve capacity bottlenecks, enhance company performance, strengthen new product development and two of existing products development can enhance the company's core competitiveness, consolidate advantages.